Elafibranor ELATIVE study now enrolling
The Phase 3 study will consist of Elafibranor 80mg for double blind period (52 to 104 weeks). After completion of the double blind period, participants will be offered the opportunity
PBC Facebook Live – March 24, 2021 7-8pm EST
No need to register. Follow Canadian PBC Society on Facebook to get a notification when the session starts!
AGM – April 24, 2021 10:00 – noon EST
Due to COVID restrictions, this business meeting will be held via ZOOM. To attend register online.
EL-FIT program helps keep liver patients fit!
El-Fit offers a custom exercise program, tailored to meet the individual needs of liver patients. Using a friendly APP, the program allows patients to set goals and track progress, as
Zydus -Saroglitazar -FDA fast track designation for PBC
Drug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug candidate Saroglitazar Mg, indicated for the treatment ofPBC Facebook Live – Wednesday December 2, 2020
Special Guest, Prof. David Jones on PBC Past, Present & Future, moderated by Dr. Gideon Hirschfield.
CymaBay -Seladelpar Phase 3 Enhance Study shows positive results
At AASLD 2020 virtual liver conference, Dr. Gideon Hirschfield presented promising Phase 3 results for Seladelpar a treatment for patients with PBC. Positive outcomes included: 78% of those in the
Escient – upcoming clinical trial for PBC itch
There is a new clinical trial aimed at PBC pruritus. While the study is currently in New Zealand and Australia, there are plans to expand the trial to PBC patients
Linerixibat (GSK2330672) Phase 2b Results
Linerixibat (GSK2330672), a drug that is being developed for PBC patients who experience itchiness, has recently published Phase 2b results. This is promising news for patients who are suffering from
Real-World Effectiveness of Obeticholic Acid – new study
Obeticholic Acid was approved in Canada in May 2017, this study describes its effectiveness in two Canadian centers. Read more.